ATE469969T1 - Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon - Google Patents
Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davonInfo
- Publication number
- ATE469969T1 ATE469969T1 AT03795363T AT03795363T ATE469969T1 AT E469969 T1 ATE469969 T1 AT E469969T1 AT 03795363 T AT03795363 T AT 03795363T AT 03795363 T AT03795363 T AT 03795363T AT E469969 T1 ATE469969 T1 AT E469969T1
- Authority
- AT
- Austria
- Prior art keywords
- human
- mcp
- antibodies
- fragment
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002267184 | 2002-09-12 | ||
| PCT/JP2003/011560 WO2004024921A1 (ja) | 2002-09-12 | 2003-09-10 | ヒト抗ヒトｍｃｐ−１抗体及び該抗体フラグメント |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469969T1 true ATE469969T1 (de) | 2010-06-15 |
Family
ID=31986692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03795363T ATE469969T1 (de) | 2002-09-12 | 2003-09-10 | Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7342106B2 (de) |
| EP (1) | EP1538207B1 (de) |
| JP (1) | JP4426449B2 (de) |
| KR (1) | KR20050042801A (de) |
| CN (1) | CN1681926A (de) |
| AT (1) | ATE469969T1 (de) |
| AU (1) | AU2003262051B2 (de) |
| CA (1) | CA2497804A1 (de) |
| DE (1) | DE60332847D1 (de) |
| DK (1) | DK1538207T3 (de) |
| WO (1) | WO2004024921A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| CA2540308C (en) | 2003-09-26 | 2013-08-06 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
| US8114964B2 (en) * | 2005-05-19 | 2012-02-14 | Centocor, Inc. | Anti-MCP-1 antibodies, compositions, methods and uses |
| PE20061444A1 (es) * | 2005-05-19 | 2007-01-15 | Centocor Inc | Anticuerpo anti-mcp-1, composiciones, metodos y usos |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| ATE554085T1 (de) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | Neue inhibitoren von glutaminylcyclase |
| WO2008077945A2 (en) * | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
| JP5930573B2 (ja) | 2007-03-01 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤の新規使用 |
| EP2142514B1 (de) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thioharnstoffderivate als glutaminylcyclaseinhibitoren |
| ES2453592T3 (es) | 2007-08-02 | 2014-04-08 | Novimmune Sa | Anticuerpos anti-RANTES y métodos de uso de los mismos |
| RU2547595C2 (ru) | 2008-08-18 | 2015-04-10 | Пфайзер Инк | Антитела против ccr2 |
| EP2328930B1 (de) | 2008-08-20 | 2014-12-24 | Probiodrug AG | Gegen das pyroglutamate monocyte chemoattractant protein-1 (mcp-1 n1pe) gerichtete antikörper |
| JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| NZ602312A (en) | 2010-03-10 | 2014-02-28 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
| CA2958195A1 (en) * | 2014-08-15 | 2016-02-18 | PixarBio Corporation | Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same |
| US20200306283A1 (en) | 2016-06-22 | 2020-10-01 | William Warren HARLESS | Cancer treatment and metastasis inhibition using an anti-cancer stem cell agent in combination with a neu1 sialidase inhibitor or a cytokine inhibitor after primary cancer treatment |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (de) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Behandlung einer erkrankung des gastrointestinaltraktes mit einem chemokin/chemokin-rezeptor-inhibitor |
| ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
| EP3883635A1 (de) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| CN112358547A (zh) * | 2020-09-30 | 2021-02-12 | 浙江大学 | 抗人cxcl-2单克隆抗体3-d3及其编码基因和应用 |
| CN112778414B (zh) * | 2020-12-31 | 2022-04-15 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0967399A (ja) | 1995-08-30 | 1997-03-11 | Mitsui Toatsu Chem Inc | 抗ｍｃｐ−１ヒトモノクローナル抗体 |
| JP4298051B2 (ja) | 1999-04-13 | 2009-07-15 | 和久 杉村 | 抗ｍｃｐ−１抗体認識ペプチドミミックス、その製造方法およびその用途 |
| US7309693B2 (en) | 2000-05-26 | 2007-12-18 | Kensuke Egashira | Preventives and remedies for pulmonary hypertension |
| GB0016138D0 (en) * | 2000-06-30 | 2000-08-23 | Novartis Ag | Organic compounds |
-
2003
- 2003-09-10 WO PCT/JP2003/011560 patent/WO2004024921A1/ja not_active Ceased
- 2003-09-10 AU AU2003262051A patent/AU2003262051B2/en not_active Ceased
- 2003-09-10 JP JP2004535928A patent/JP4426449B2/ja not_active Expired - Fee Related
- 2003-09-10 CA CA002497804A patent/CA2497804A1/en not_active Abandoned
- 2003-09-10 DE DE60332847T patent/DE60332847D1/de not_active Expired - Lifetime
- 2003-09-10 EP EP03795363A patent/EP1538207B1/de not_active Expired - Lifetime
- 2003-09-10 US US10/527,823 patent/US7342106B2/en not_active Expired - Fee Related
- 2003-09-10 AT AT03795363T patent/ATE469969T1/de active
- 2003-09-10 DK DK03795363.5T patent/DK1538207T3/da active
- 2003-09-10 KR KR1020057004050A patent/KR20050042801A/ko not_active Withdrawn
- 2003-09-10 CN CNA038215527A patent/CN1681926A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2004024921A1 (ja) | 2006-01-12 |
| AU2003262051A1 (en) | 2004-04-30 |
| JP4426449B2 (ja) | 2010-03-03 |
| AU2003262051B2 (en) | 2008-09-25 |
| EP1538207B1 (de) | 2010-06-02 |
| KR20050042801A (ko) | 2005-05-10 |
| DK1538207T3 (da) | 2010-07-05 |
| CA2497804A1 (en) | 2004-03-25 |
| WO2004024921A1 (ja) | 2004-03-25 |
| EP1538207A4 (de) | 2006-05-24 |
| EP1538207A1 (de) | 2005-06-08 |
| US20060246069A1 (en) | 2006-11-02 |
| CN1681926A (zh) | 2005-10-12 |
| DE60332847D1 (de) | 2010-07-15 |
| US7342106B2 (en) | 2008-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE469969T1 (de) | Menschlicher anti-mensch-mcp-1-antikorper sowie antikorperfragment davon | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| ATE476992T1 (de) | Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper | |
| PT1639011E (pt) | Anticorpos (dab) de domínio único peguilados | |
| NZ599196A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| CY1118063T1 (el) | ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΑΝΘΡΩΠ1ΝΗΣ IgE ΥΨΗΛΗΣ ΣΥΓΓΕΝΕΙΑΣ | |
| ATE530195T1 (de) | Bispezifische einzelketten-fv-antikörper-moleküle und anwendungsverfahren dafür | |
| PE20020319A1 (es) | ANTICUERPOS PARA IL-1ß HUMANA | |
| NZ604090A (en) | Human anti-b7rp1 neutralizing antibodies | |
| EP1885399A4 (de) | Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung | |
| ATE476994T1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| NZ595450A (en) | Antibodies to M-CSF | |
| HRP20050986A2 (en) | Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof | |
| NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
| GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
| CY1109817T1 (el) | Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου | |
| NO20026063D0 (no) | Antistoffer mot human MCP-1 | |
| PT1308507E (pt) | Anticorpo monoclonal anti-núcleo de hcv | |
| ATE517920T1 (de) | Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1) | |
| ITMI20031127A1 (it) | Anticorpi anti-hgf-r e loro uso | |
| DE60136527D1 (de) | Antikörper gegen eotaxin und deren verwendung | |
| DE60238556D1 (de) | Humane antikörper gegen das humane glycoprotein vi und deren verwendung | |
| DK1411962T3 (da) | Terapi for pancreacancer med monoklonalt stof | |
| DE602004031635D1 (de) | Tumorvaskulatur zielrichtung mittels verwendung eines gegen fibronectin ed-b radiomarkierten antikörpers l19 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1538207 Country of ref document: EP |